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Abstract
Purpose Prostate cancer management strategies are
evolving with increased understanding of the disease.
Specifically, there is emerging evidence that ‘‘low-risk’’
cancer is best treated with observation, while localized
‘‘high-risk’’ cancer requires aggressive curative therapy. In
this study, we evaluated trends in management of prostate
cancer in New Hampshire to determine adherence to evidence-based practice.
Methods From the New Hampshire State Cancer Registry, cases of clinically localized prostate cancer diagnosed in 2004–2011 were identified and classified
according to D’Amico criteria. Initial treatment modality
was recorded as surgery, radiation therapy, expectant
management, or hormone therapy. Temporal trends were
assessed by Chi-square for trend.
Results Of 6,203 clinically localized prostate cancers
meeting inclusion criteria, 34, 30, and 28 % were low-,
intermediate-, and high-risk disease, respectively. For lowrisk disease, use of expectant management (17–42 %,
p \ 0.001) and surgery (29–39 %, p \ 0.001) increased,
while use of radiation therapy decreased (49–19 %,
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p \ 0.001). For intermediate-risk disease, use of surgery
increased (24–50 %, p \ 0.001), while radiation decreased
(58–34 %, p \ 0.001). Hormonal therapy alone was rarely
used for low- and intermediate-risk disease. For high-risk
patients, surgery increased (38–47 %, p = 0.003) and radiation decreased (41–38 %, p = 0.026), while hormonal
therapy and expectant management remained stable.
Discussion There are encouraging trends in the management of clinically localized prostate cancer in New
Hampshire, including less aggressive treatment of low-risk
cancer and increasing surgical treatment of high-risk
disease.
Keywords Prostate cancer  Management trends  Risk
stratification  Active surveillance  Surgery

Introduction
Prostate cancer is the most common cancer diagnosis in
men in the USA, with *220,000 new diagnosis projected
in 2015. While most prostate cancer is slow-growing and
non-lethal, a subset of cancers will become metastatic and
cause mortality (*28,000 men in 2015) [1]. A newly diagnosed cancer is categorized as ‘‘low,’’ ‘‘intermediate,’’ or
‘‘high risk’’ based on biopsy findings, prostate-specific
antigen (PSA) level, and physical examination findings
(presence or absence of prostate nodularity) [2]. This risk
category reflects the likelihood of progression and lethality
and is used for making treatment decisions in conjunction
with patient age, health status, and other concerns such as
sexual and urinary function.
Longitudinal data have demonstrated a high rate of
treatment for all risk categories [3]. While aggressive
treatment in the form of surgery or radiation therapy is
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appropriate for more aggressive cancers, ‘‘low-risk’’ disease can often be safely observed, and patients can be
spared the side effects of treatment. There are emerging
data that ‘‘expectant management,’’ including active
surveillance (with follow-up biopsy) and watchful waiting
(with monitoring based on symptoms only), is safe and
associated with a low risk of cancer mortality for appropriate low-risk patients. In fact, a study with a follow-up
time of 18 years found that patients with low-risk cancer
were far more likely to die from causes other than prostate
cancer [4]. These approaches have been incorporated into
recent treatment guidelines by the American Urological
Association, European Association of Urology, and the
National Comprehensive Cancer Network [6–8].
Nonetheless, there continues to be a high rate of aggressive
treatment of low-risk cancer, incurring treatment morbidity
without a concomitant survival benefit [5].
‘‘High-risk’’ prostate cancer presents the opposite challenge—many patients are treated with non-curative therapies such as testosterone suppression or ‘‘hormone
therapy,’’ when they might benefit from aggressive local
treatment with radiation or surgery [9, 10]. This has presented a quality of care concern [11]. Additionally, while
radiation therapy has been used more commonly for
treatment of high-risk disease, studies have demonstrated
similar long-term outcomes between radiation therapy and
radical prostatectomy, with a suggestion of a benefit from
surgery for selected patients [12, 13] Ultimately, there are
multiple treatment options for all risk categories, and thus
treatment decisions are often considered ‘‘preference-sensitive’’ and emerge from a nuanced conversation between
provider and patient [14, 15].
In this paper, we examined trends in the management of
localized prostate cancer in New Hampshire using state
cancer registry data. We sought to evaluate whether statewide practices are consistent with our growing understanding of prostate cancer behavior and potential optimal
therapies (i.e., increasing use of expectant management for
low-risk cancer and definitive therapy for higher-risk
cancer).
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defined as AJCC 7th Edition T Stage 1–2. Cases were
excluded for the following reasons: cancer confirmation
only by death certificates, autopsy, or pathology or nursing
home records; patients diagnosed and treated by the
Veterans Health Adminstration due to restrictions in data
use; evidence of lymph node involvement, N1, or metastasis, M1; unclassified D’Amico risk category due to
missing or unconfirmed preoperative data. The study period was initiated in 2004 as this is the first year in which
complete data were recorded, including preoperative PSA,
clinical stage, and biopsy Gleason score. 2011 was the
most recent year with complete information.
Cancers were stratified according to D’Amico risk
categories. Men with PSA \10, biopsy Gleason score 6,
clinical stage T1c, and/or clinical stage T2a were classified
as low risk, men with PSA 10–20, biopsy Gleason score 7,
and/or clinical stage T2b as intermediate risk, and men
with PSA [20, biopsy Gleason score 8?, and/or clinical
stage T2c? as high risk [2]. The initial treatment was
recorded as surgical therapy, radiation (external beam radiotherapy and/or brachytherapy), primary androgen deprivation (ADT) therapy (men on ADT plus radiation were
counted as initial radiation therapy), or expectant management (no therapy recorded within 6 months). The data
from the cancer registry were not granular enough to differentiate ‘‘active surveillance’’ (monitoring with follow-up
biopsy) from ‘‘watchful waiting’’ (symptomatic monitoring
only). Subsequent treatment was not recorded in our analysis as our goal was to study initial therapy rather than
adjuvant or salvage therapies. Men who underwent subsequent treatment by another modality were not excluded,
however.
Temporal trends were assessed by Chi-square for trend,
with a p value of \0.05 considered significant. This investigation was approved by the Dartmouth Committee for
the Protection of Human Subjects, and data use was approved by the New Hampshire Department of Public
Health Services.

Results
Materials and methods
Clinically localized (non-metastatic) prostate cancers diagnosed from 2004 to 2011 were identified in the New
Hampshire State Cancer Registry (NHSCR). NHSCR is a
statewide, population-based cancer surveillance program
that collects incidence data on all cancer cases diagnosed
or treated in New Hampshire residents, including clinical
data such as stage, a preoperative Gleason grade on a
transrectal biopsy or a transurethral resection specimen,
PSA, and initial treatment. Clinically localized disease was
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Of the 7,706 potentially eligible cases, 1,062 were excluded because the preoperative D’Amico risk category
could not be calculated due to a missing biopsy Gleason
score or an uncertain source (biopsy vs. surgical pathology). A further 441 were excluded because the D’Amico
risk category was unknown due to other missing data. The
remaining 6,203 men had clinically localized prostate
cancer and met the inclusion criteria. Demographics are
shown in Table 1. The mean age was 65.7 ± 9.3 years.
There was an average annual increase in diagnosis of
2.2 %, matching population growth among men over the

Cancer Causes Control (2015) 26:923–929

925

Table 1 Population demographics
Low risk
(n = 2,302)

Intermediate risk
(n = 1,997)

High risk
(n = 1,904)

No.

No.

No.

%

%

v2

All cases
(n = 6,203)
%

No.

%

Age

0.000

\50

84

50–65
66–75

1,249
808

[75

161

Mean, SD

3.6

33

1.7

34

1.8

54.3
35.1

910
768

45.6
38.5

780
703

41.0
36.9

2,939
2,279

47.4
36.7

7.0

286

14.3

387

20.3

834

13.4

63.6, 8.1

66.11, 8.4

67.4, 9.4

151

2.4

65.6, 8.8

Residencea

0.000

Rural

902

39.3

905

45.4

903

47.6

2,710

43.8

Urban

1,393

60.7

1,087

54.6

995

52.4

3,475

56.2

7.5

139

7.3

Marital status

0.000

Single

174

7.6

Married/common law

1,811

Divorced/separated

164

7.1

145

7.3

135

7.1

444

7.2

Widowed

76

3.3

84

4.2

116

6.1

276

4.4

Unknown

77

3.3

57

2.9

98

5.1

232

3.7

78.7

150
1,561

78.2

1,416

74.4

463
4,788

7.5
77.2

Calendar year

0.000

2004

239

10.4

143

7.2

256

13.4

642

10.4

2005
2006

211
256

9.2
11.1

155
214

7.8
10.7

224
239

11.8
12.6

593
710

9.6
11.4

2007

282

12.3

264

13.2

246

12.9

792

12.8

2008

310

13.5

307

15.4

233

12.2

848

13.7

2009

294

12.8

294

14.8

242

12.8

830

13.4

2010

370

16.0

290

14.5

235

12.3

893

14.4

2011

340

14.8

330

16.5

228

12.0

894

14.4

1,595

79.9

1,080

56.7

4,977

80.2

20.1

235

12.3

637

10.3

26.2

498

8.0

PSA lab value

0.000

\10

2,302

10 to \20

0

0.0

402

20?

0

0.0

0

0.0

498

Test ordered, result not in chart

0

0.0

0

0.0

5

0.3

5

0.1

Test not done

0

0.0

0

0.0

8

0.4

8

0.1

Unknown if done

0

0.0

0

0.0

78

4.1

78

1.3

100.0

Biopsy Gleason score

0.000

B6

2,302

234

11.7

478

25.1

3,014

48.6

7
8–10

0
0

100.0
0.0
0.0

1,763
0

88.3
0.0

551
864

28.9
45.4

2,314
864

37.3
13.9

No BX/TURP performed

0

0.0

0

0.0

4

0.2

4

0.1

Unknown if test done

0

0.0

0

0.0

7

0.4

7

0.1

AJCC cT

a

0.000

1

1,871

81.3

1,442

72.2

2a

254

2b

0

2c?
2NOS
Unknown

582

30.6

11.0

255

12.8

100

5.3

609

9.8

0.0

162

8.1

71

3.7

233

3.8

0

0.0

0

0.0

1,018

177

7.7

138

6.9

104

5.5

419

6.8

0

0.0

0

0.0

29

1.5

29

0.5

53.5

3,895

1,018

62.8

16.4

5 zip codes in New Hampshire have not been classified as either rural or urban, leading to a smaller n
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age of 65 in New Hampshire. There was a shift in the age
of diagnosed patients during the study period; 46 % of
patients were under 65 years of age in 2004 but 56 % in
2011. Similarly, 16 % of diagnosed men were older than
75 in 2004, but 11 % in 2011. Diagnoses were similarly
distributed within calendar years. Overall, 2,302 (34 %),
1,997 (30 %), and 1,904 (28 %) men were diagnosed with
low-, intermediate-, and high-risk disease, respectively.
There was a proportional decrease in high-risk disease
(39–27 % of all cancer diagnosis, p \ 0.001) and increase
in intermediate disease (26–36 %, p \ 0.001). Shifts in
low-risk cancer diagnosis did not reach significance.
Overall, there was an increase in use of surgery and expectant management as first treatment choice, and a decrease in radiation and primary androgen deprivation (see
Fig. 1), although patterns varied by D’Amico risk category.
Figure 2 depicts trends of initial treatments for patients
with low-risk disease. Use of expectant management more
than doubled (17–42 %) during the study period. Surgery
was also performed more often (29–39 %). The use of
initial radiation therapy decreased significantly (49–19 %),
as did treatment with initial androgen deprivation
(5–0.3 %).
For intermediate-risk patients, surgery rates doubled
(24–50 %), while radiation (58–34 %) and primary hormonal deprivation decreased (9–3 %) as shown in Fig. 3.
There was no statistically significant change in use of expectant management, which was used in 13 % of cases.
Among patients with high-risk disease, surgery and radiation were each used as initial treatment in about 40 % of
the cases with fluctuations between years as shown in
Fig. 4. There was, however, a statistically significant trend
toward increased surgical treatment (38–47 %, p = 0.003)
and a decrease in radiation therapy (41–38 %, p = 0.026).
The changes in hormonal therapy and expectant management did not display a statistically significant trend.
The median age of men in each treatment group was
60.4 ± 6.9 for surgery, 68.8 ± 7.2 for radiation,

Fig. 1 Changes in initial
treatment modality for clinically
localized prostate cancer by
calendar year. Trends are
statistically significant with a
p value \0.001 for all treatment
modalities

68.9 ± 9.4 for expectant management, and 73.2 ± 8.6 for
initial hormonal therapy.

Discussion
Prostate cancer is a common disease that is generally nonlethal; however, it can also behave aggressively leading to
metastasis and death. Initial ‘‘risk categorization’’ based on
laboratory, biopsy, and physical examination data reflects
the likelihood of an adverse outcome and helps to inform
decisions regarding treatment [1]. Surgery (radical prostatectomy) and radiation therapy (external beam therapy and/
or radioactive seed therapy) are first-line interventions for
localized prostate cancer [6]. Notably, there have been no
prospective, randomized trials comparing surgery and radiation in this setting; data regarding comparative effectiveness are limited to retrospective, matched cohort trials
that cannot avoid selection bias [2, 16, 17]. Thus, absent
level 1 evidence favoring one therapy, decisions for those
pursuing treatment frequently depend on patient and provider preferences and resource availability [14, 15]. An
alternative strategy for management of localized cancer is
observation. This is particularly considered for low-risk
disease, as it has a low risk of progression, and patients will
generally die from another cause [18, 19]. As surgery and
radiation therapy have well-described morbidity (e.g.,
erectile, urinary, and/or bowel dysfunction), monitoring a
low-risk cancer is often a sensible approach to balance
risks and benefits, and to optimize quality of life [20]. Finally, hormone therapy alone, also called androgen deprivation therapy (ADT), is a treatment for metastatic cancer
that can reduce morbidity but has not been shown to improve survival, and is considered inappropriate as singular
therapy in cases of localized disease [6–8].
We performed this study to evaluate trends in management of localized prostate cancer in New Hampshire and to
understand whether they reflect our growing understanding

ALL CASES

60%
50%
40%

Expectant Management

30%

Surgery
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20%
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%
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Fig. 2 Changes in initial
treatment modality for D’Amico
low risk clinically localized
prostate cancer by calendar
year. Trends are statistically
significant with a p value
\0.001 for all treatment
modalities
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LOW RISK

60%
50%

Expectant
Management

40%

Surgery

30%
Radiaon
20%
Androgen deprivaon
10%
%
2004

Fig. 3 Changes in initial
treatment modality for D’Amico
intermediate risk clinically
localized prostate cancer by
calendar year. Trends are
statistically significant with a
p value \0.001 for surgery,
radiation and androgen
deprivation

2005

2006

2007

2008

2009

2010

2011

INTERMEDIATE RISK

70%
60%
50%

Expectant Management
40%

Surgery

30%

Radiaon

20%

Androgen deprivaon

10%
%
2004

Fig. 4 Changes in initial
treatment modality for D’Amico
intermediate risk clinically
localized prostate cancer by
calendar year. Trends are
statistically significant with for
surgery (p = 0.003) and
radiation (p = 0.026)

2005

2006

2007

2008

2009

2010

2011

HIGH RISK

60%
50%
40%

Expectant Management

30%

Surgery
Radiaon

20%

Androgen deprivaon
10%
%
2004

2005

2006

of appropriate practice. We demonstrated several findings
that are encouraging regarding the quality of treatment.
Perhaps most importantly, we found that observation or an
‘‘expectant management’’ strategy has become increasingly
common as first-line treatment for low-risk disease. These
trends reflect emerging data from observational studies that
such strategies are safe and appropriate for most low-risk
patients [20]. A study by Weiner et al. [21] recently examined the utilization of non-curative initial management
in the Surveillance, Epidemiology and End Result Program
(SEER) and National Cancer Data Base (NCDB). These
authors also found a significant rise in expectant

2007

2008

2009

2010

2011

management for low-risk cancer (SEER 20–31 %, NCDB
12–21 % from 2004 to 2010); however, the shift toward
this approach in New Hampshire was more dramatic
(18–42 % from 2004 to 2011). New Hampshire is largely a
rural state; however, there are regional referral centers
where most patients are treated. Thus, we postulate that
consolidation of care at certain centers has led to more
rapid uptake of expectant management for low-risk disease.
The New Hampshire State Cancer Registry collects the
same core set of variables as other national registries such
as SEER or NCDB, and it resembles SEER in that it produces population-based data. NCDB, however, does not
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produce population-based statistics but collects data from
hospitals that are accredited by the American College of
Surgeons Commission on cancer.
Despite these encouraging trends, our data also
demonstrate that the overall treatment rate for low-risk
cancer is high ([50 % in 2011). While this likely reflects
continued overtreatment of many patients, it is notable that
selected cases of low-risk cancer should be treated aggressively, e.g., patients with high-volume disease, family
history of early mortality from prostate cancer, and significant anxiety associated with the monitoring process.
Additional studies are needed to determine whether patients with low-risk cancer are being appropriately selected
for treatment, and how to further encourage observational
strategies to reduce overtreatment.
Interestingly, our data demonstrate increasing use of
surgical treatment for low-risk cancer with a parallel decrease in radiation therapy. Reasons for this ‘‘exchange’’ of
interventions are unclear, though the advent of less invasive forms of prostatectomy (i.e., robotic surgery), which
was introduced to New Hampshire during the study period,
may contribute. For intermediate-risk cancer, trends
demonstrate a similar rise in use of surgery with a decrease
in radiation therapy. For this risk category, treatment is
recommended for most patients, provided they do not have
a significantly shortened life expectancy, though there are
no strict guidelines favoring surgery or radiation therapy
[22]. The rise in use of surgical therapy likely reflects diverse factors that cannot be captured in this study, though
this is a ripe area of study to determine factors influencing
treatment decisions for these patients.
For high-risk cancer, we demonstrate a significant increase in the use of surgical therapy, with a slight decrease
in use of radiation. While radiation therapy has been the
historical default treatment option for clinically localized
high-risk disease, surgical treatment has been increasingly
considered as a primary treatment. Data have emerged that
surgery may achieve cure with wide surgical resection and
pelvic lymph node removal, as well as a favorable outcome
when used in concert with adjuvant or salvage radiation
and hormone therapy [23]. In the contemporary treatment
arena, it is critical that surgery be discussed with and
contemplated by those with localized high-risk cancer, as it
may better meet patient preferences than primary radiation
therapy. Thus, it is encouraging that aggressive local
therapy with surgery alone, or as a starting point for a
multimodal approach, is being offered to patients with
high-risk cancer. Finally, we found a low, stable rate of
hormone monotherapy for high-risk cancer. This is encouraging, as hormone therapy lacks a survival benefit for
clinically localized disease, may have significant side effects, and has been shown to be overused in the treatment
of these patients [9, 10].

123

Cancer Causes Control (2015) 26:923–929

There are numerous variables that may affect treatment
choices for prostate cancer, including screening patterns
and stage migration. Studies have demonstrated a decrease
in rates of screening, particularly in older patients, after the
2008 United States Preventive Services Task Force recommendations [24]. While our data did not incorporate
screening practices, we did find no decrease in overall
cancer rates during the study period, though there were
some shifts in risk categories; specifically, more intermediate-risk and fewer higher-risk cancers were identified.
While these changes may impact overall treatment trends,
we report treatment decisions within risk categories which
make these changes less relevant. In terms of demographic
shifts, there were fewer diagnoses in older men during our
study period, however, this change was small and we do
not believe this significantly impacted treatment decisions.
There are some limitations of our study that warrant
discussion. The registry data did not contain comorbidity
data that might be used to assess competing risks of death
and how these might impact treatment practices. As such,
we were only able to capture trends in treatment without
assessing potential medical confounders. Also, while the
data collected by NHSCR are of high quality, 19.5 % of
eligible cases were excluded due to missing clinical data. It
is important, though, to interpret this number in light of our
strict inclusion criteria that required clinical stage, PSA,
and biopsy Gleason score for accurate categorization. We
could not assess differences in disease risk between included and excluded patients because the latter, by
definition, had incomplete data.
Another limitation of our study is our definition of
‘‘expectant management’’ as those with no intervention
within 6 months of diagnosis. This is the conventional
definition used in the literature for population-based studies, though it may include some patients who had delayed
treatment but nonetheless had planned on a definitive intervention, for instance, in the 6- to 12-month window.
Finally, our data represent practice within a largely rural
state and may not be generalizable to other regions. In
particular, travel distances and extreme winter weather
may influence treatment decisions, especially when multiple trips for treatment would be required [25]. We are
currently evaluating the impact of distant to a radiation
facility on treatment decisions and hope to report this in a
future manuscript.

Conclusion
There are encouraging trends in the management of
clinically localized prostate cancer in New Hampshire, including increased observation of low-risk cancer, and increasing surgical treatment of high-risk disease. Continued
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efforts to study and refine practice patterns will enable us to
optimize our approaches to this heterogeneous disease.
Conflict of interest The authors declare that they have no conflicts
of interest.
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